Novel effects other than antisecretory action and off-label use of proton pump inhibitors

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 1, 2005, Pages 59-67

  Suzuki, Hidekazu ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; AG 1812; AG 2000; ANTACID AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SULFENAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; CELL REGENERATION; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG USE; DYSPEPSIA; ENTERITIS; GASTRITIS; GASTROINTESTINAL DISEASE; GENERAL PRACTITIONER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LICENSING; NONHUMAN; PEPTIC ULCER; PRESCRIPTION; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; STOMACH MUCOSA; ZOLLINGER ELLISON SYNDROME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTRIC ACID; GASTROINTESTINAL AGENTS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMPS;

EID: 12744275054     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.1.59     Document Type: Review

References (55)

1. SANDERS SW. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin. Ther. (1996) 18:2-34.
2. RICHARDSON P, HAWKEY CJ, STACK WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs (1998) 56:307-335.
3. + ATPase. Ann. Rev. Pharmacol. Toxicol. (1995) 35:277-305.
4. LINDBERG P, NORDBERG P, ALMINGER T, BRANDSTROM A, WALLMARK B: The mechanism of action of the gastric acid secretion inhibitor omeprazole. J. Med. Chem. (1986) 29:1327-1329.
5. BRANDSTROM A, LINDBERG P, JUNGGREN U: Structure activity relationships of substituted benzimidazoles. Scand. J. Gastroenterol. Suppl. (1985) 108:15-22.
6. HOWDEN CW: Optimizing the pharmacology of acid control in acid-related disorders. Am. J. Gastroenterol. (1997) 92 17S-19S; discussion 19S-21S.
7. TUNIS SR, SHEINHAIT IA, SCHMID CH, BISHOP DJ, ROSS SD: Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis. Clin. Ther. (1997) 19 743-757.
8. MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current European concepts in the management of Helicobacter pylori infection the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur. J. Gastroentrol. Hepatol. (1997) 9:1-2.
9. MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. (2002) 16:167-180.
10. BLUM AL, TALLEY NJ, O'MORAIN C et al.: Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N. Engl. J. Med. (1998) 339 1875-1881.
11. TALLEY NJ, JANSSENS J, LAURITSEN K, RACZ I, BOLLING-STERNEVALD E: Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br. Med. J. (1999) 318 833-837.
12. TALLEY NJ, VAKIL N, BALLARD ED 2nd, FENNERTY MB: Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N. Engl. J. Med. (1999) 341:1106-1111.
13. MCCOLL K, MURRAY L, EL-OMAR E et al.: Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N. Engl. J. Med. (1998) 339:1869-1874.
14. MOAYYEDI P, SOO S, DEEKS J, FORMAN D et al.: Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. Br. Med. J. (2000) 321:659-664.
15. LAINE L, SCHOENFELD P, FENNERTY MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomised, controlled trials. Ann. Intern. Med. (2001) 134 361-369.
16. SUZUKI H, MASAOKA T, SAKAI G, ISHII H, HIBI T. Improvement of gastrointestinal quality of life (QOL) scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J. Gastroenterol. Hepatol. (2005) (In Press).
17. BASHFORD JN, NORWOOD J, CHAPMAN SR: Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. Br. Med. J. (1998) 317:452-456.
18. GOLD BD: Gastroesophageal reflux disease: could intervention in childhood reduce the risk of later complications? Am. J. Med. (2004) 117:23S-29S.
19. HOWDEN CW: Management of acid-related disorders in patients with dysphagia. Am. J. Med. (2004) 117:44S-48S.
20. FRESTON JW: Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. Am. J. Med. (2004) 117:14S-22S.
21. SUZUKI H, MASAOKA T, NOMURA S et al.: Current consensus on the diagnosis and treatment of H.pylori-associated gastroduodenal disease. Keio J. Med. (2003) 52:163-173.
22. SACHS G, SHIN JM, MUNSON K et al.: Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2000) 14:1383-1401.
23. KLOTZ U: Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet. (2000) 38:243-270.
24. WARREN JR, MARSHALL BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet (1983) i 1273-1275.
25. VAKIL N, LANZA F, SCHWARTZ H, BARTH J: Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther. (2004) 20:99-107.
26. HIRAYAMA F, TAKAGI S, KUSUHARA H, IWAO E, YOKOYAMA Y, IKEDA Y: Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J. Gastroenterol. (1996) 31:755-757.
27. WATANABE T, TADA M, NAGAI H, SASAKI S, NAKAO M: Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology (1998) 115:642-648.
28. HONDA S, FUJIOKA T, TOKIEDA M, SATOH R, NISHIZONO A, NASU M: Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. (1998) 58:4255-4259.
29. SUZUKI H, MORI M, SETO KB et al.: H. pylori-associated gastric pro- and anti-oxidant formation in Mongolian gerbils. Free Radic. Biol. Med. (1999) 26:679-684.
30. SUZUKI H, MASAOKA T, HOSODA H et al.: Helicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils. Gut (2004) 53:187-194.
31. SUZUKI H, MIYAZAWA M, NAGAHASHI S et al.: Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils. J. Gastroenterol. Hepatol. (2003) 18:787-795.
32. NAKAJIMA N, KUWAYAMA H, IWASAKI A, ARAKAWA T. Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth. J. Clin. Gastroenterol. (1995) 20:S90-S92.
33. KUIPERS EJ, UYTERLINDE AM, PENA AS et al.: Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am. J. Gastroenterol. (1995) 90:1401-1406.
34. KUIPERS EJ, LUNDELL L, KLINKENBERG-KNOL EC et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. (1996) 334:1018-1022.
35. MEINING A, BOSSECKERT H, CASPARY WF, NAUERT C, STOLTE M: H2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment. Pharmacol. Ther. (1997) 11:729-734.
36. UEMURA N, OKAMOTO S, YAMAMOTO S et al.: Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment. Ther. (2000) 14:1345-1352.
37. STOLTE M, MEINING A, SCHMITZ JM, ALEXANDRIDIS T, SEIFERT E: Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (1998) 12:247-253.
38. GRAHAM DY. OPEKUN AR, YAMAOKA Y, OSATO MS, EL-ZIMAITY HM: Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment. Pharmacol. Ther. (2003) 17:193-200.
39. SUZUKI M, SUZUKI H, KITAHORA T et al.: Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori. Aliment. Pharmacol. Ther. (2002) 16 Suppl. 2):229-234.
40. KUIPERS EJ, NELIS GF, KLINKENBERG-KNOL EC et al.: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut (2004) 53:12-20.
41. PEURA DA, KOVACS TO, METZ DC, SIEPMAN N, PILMER BL, TALLEY NJ: Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomised, placebo-controlled trials. Am. J. Med. (2004) 116:740-748.
42. ASHORN M, RAGO T, KOKKONEN J, RUUSKA T, RAUTELIN H, KARIKOSKI R: Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain: double blind randomised placebo-controlled trial. J. Clin. Gastroenterol., (2004) 38:646-650.
43. SUZUKI M, NAKAMURA M, MORI M, MIURA S, TSUCHIYA M, ISHII H: Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J. Clin. Gastroenterol. (1995) 20(Suppl. 2):S93-S96.
44. FUKUDA T, ARAKAWA T, SHIMIZU Y, OHTANI K, HIGUCHI K, KOBAYASHI K: Effects of lansoprazole on ethanol-induced injury and PG synthetic activity in rat gastric mucosa. J. Clin. Gastroenterol. (1995) 20(Suppl. 2):S5-S7.
45. YOSHIDA N, YOSHIKAWA T, TANAKAY et al.: A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment. Pharmacol. Ther. (2000) 14(Suppl. 1):74-81.
46. LAMOULIATTE H: Effect of lansoprazole on Helicobacter pylori. Clin. Ther. (1993) 15(Suppl. B):32-36.
47. KUHLER TC, SWANSON M, SHCHERBUCHIN V, LARSSON H, MELLGARD B, SJOSTROM JE: Structure-activity relationship of 2-[[(2-pyridyl) methyl]thio]-1H-benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy. J. Med. Chem. (1998) 41:1777-1788.
48. MEGRAUD F, BOYANOVA L, LAMOULIATTE H: Activity of lansoprazole against Helicobacter pylori. Lancet (1991) 337 1486.
49. IWAHI T, SATOH H, NAKAO M et al.: Lansoprazole, a novel benzimidazole proton pump inhibitor, its related compounds have selective activity against Helicobacter pylori. Antimicrob. Agents Chemother. (1991) 35:490-496.
50. HORN J: The proton-pump inhibitors: similarities and differences. Clin. Ther. (2000) 22:266-280; discussion 265.
51. FIGURA N, CRABTREE JE, DATTILO M: In-vitro activity of lansoprazole against Helicobacter pylori. J. Antimicrob. Chemother. (1997) 39:585-590.
52. SUZUKI H, NISHIMOTO S, KURABAYASHI K, ABIKO Y, MASAOKA T, ISHII H: Effect of lansoprazole on the motility of H. pylori - examination, using a novel dark field image digital analysis system. Gastroenterology (2004) 126:A403.
53. DICKINSON JB: Is omeprazole helpful in inflammatory bowel disease? J. Clin. Gastroenterol. (1994) 18:317-319.
54. SUZUKI H, MASAOKA T, MINEGISHI Y, MOTOSUGI Y, MIURA S, ISHII H: Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. Wound Repair Regen. (2004) 12:93-99.
55. IWAI-KANAI E, HASEGAWA K, SAWAMURA T et al.: Activation of lectin-like oxidized low-density lipoprotein receptor-1 induces apoptosis in cultured neonatal rat cardiac myocytes. Circulation (2001) 104:2948-2954.